Valneva
Created in 2013
- BETA
Trend leader (A+)
Existing signals make this entity one of the most dynamic startups Social networks
8,486 38,874Activities
Technologies
Entity types
Location
6 Rue Alain Bombard, 44800 Saint-Herblain, France
Saint-Herblain
France
Employees
Scale: 501-1000
Estimated: 654
SIREN
422497560Engaged corporates
23
10 6Added in Motherbase
4 years ago
biotech Value proposition
Specialty vaccine company focused on prevention of infectious diseases with major unmet need, such as Lyme & chikungunya
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs.
We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.
We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines, including the world’s first and only chikungunya vaccine, as well as certain third-party vaccines.
Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats.
Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the U.S. with approximately 700 employees.
vaccinesOriginal language
Specialty vaccine company focused on prevention of infectious diseases with major unmet need, such as Lyme & chikungunya
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs.
We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.
We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines, including the world’s first and only chikungunya vaccine, as well as certain third-party vaccines.
Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats.
Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the U.S. with approximately 700 employees.
Home - Valneva
We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs.
https://valneva.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 UK Atomic Energy Authority Research, National and local authorities | UK Atomic Energy Authority Research, National and local authorities | Other 23 Jul 2020 | | |
 Nasdaq Finance, Financial Services | Nasdaq Finance, Financial Services | Capitalistic Partnership Not event 6 May 2021 5 Jan 2023 | | |
 BNP Paribas Bank, Banking | BNP Paribas Bank, Banking | Not capitalistic Not partnership Event 1 Oct 2020 | | |
 Groupe VYV Insurance | Groupe VYV Insurance | Other 1 Dec 2021 | | |
 Région Pays de la Loire National and local authorities, Government Administration | Région Pays de la Loire National and local authorities, Government Administration | Other 1 Feb 2021 | | |
 AstraZeneca Pharmaceutical, Pharmaceutical Manufacturing | AstraZeneca Pharmaceutical, Pharmaceutical Manufacturing | Other 20 Jan 2024 | | |
 Le Journal des Entreprises Media, Newspaper Publishing | Le Journal des Entreprises Media, Newspaper Publishing | Other 17 Jan 2024 | | |
 Eurostat European Union, Environmental Services | Eurostat European Union, Environmental Services | Other 9 Aug 2021 | | |
 Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Other 30 Nov 2023 | | |
 GSK Pharmaceutical, Pharmaceutical Manufacturing | GSK Pharmaceutical, Pharmaceutical Manufacturing | Not capitalistic Partnership Not event 30 Nov 2023 | | |